PFE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	45.37M
Średni wolumen	41.44M
Kapitalizacja rynkowa	157.04B
EPS	$0 ( 2024-05-01 )
Następna data zysków	( $0 ) 2024-07-30
Last Dividend	$0.410 ( 2023-11-09 )
Next Dividend	$0 ( N/A )
P/E	-556.20
ATR14	$0.0170 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Damico Jennifer B.	Buy	55	Phantom Stock Units SSP
2024-04-30	Bourla Albert	Buy	20	Phantom Stock Units SSP
2024-04-25	Quincey James	Buy	8 116	Phantom Stock Units
2024-04-25	Smith James C	Buy	8 116	Phantom Stock Units
2024-04-25	Nora Johnson Suzanne M	Buy	8 116	Phantom Stock Units

INSIDER POWER
70.76
Last 100 transactions
Buy: 4 322 762 \| Sell: 745 543

Wolumen Korelacja

Długi: 0.64 (weak)

Krótki: 0.89 (strong)

Signal:(67.183) Same movement expected

Pfizer Inc Korelacja

10 Najbardziej pozytywne korelacje
PCQ	0.969
ZME	0.962
CHGG	0.951
RSF	0.947
GDMA	0.946
TPL	0.941
CALX	0.939
EVTL	0.937
PCK	0.936
K	0.93

10 Najbardziej negatywne korelacje
WWW	-0.954
HCI	-0.953
NGL-PB	-0.95
FSNB	-0.949
LOCC	-0.949
LHC	-0.948
VNT	-0.947
CRH	-0.945
FTAI	-0.942
JMP	-0.94

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pfizer Inc Korelacja - Waluta/Towar

0.59
( weak )

0.79
( moderate )

0.00
( neutral )

-0.23
( neutral )

0.10
( neutral )

-0.85
( strong negative )

Pfizer Inc Finanse

Annual	2023
Przychody:	$58.50B
Zysk brutto:	$29.28B (50.06 %)
EPS:	$0.380

FY	2023
Przychody:	$58.50B
Zysk brutto:	$29.28B (50.06 %)
EPS:	$0.380

FY	2022
Przychody:	$100.33B
Zysk brutto:	$65.99B (65.77 %)
EPS:	$5.59

FY	2021
Przychody:	$81.29B
Zysk brutto:	$50.47B (62.08 %)
EPS:	$3.92

Financial Reports:

No articles found.

Pfizer Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.400 (N/A)	$0.400 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0.410 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Pfizer Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 1.990 - low (50.00%) | Divividend Growth Potential Score: 2.67 - Decrease likely (46.58%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00316	1972-08-29
Last Dividend	$0.410	2023-11-09
Next Dividend	$0	N/A
Payout Date	2023-12-04
Next Payout Date	N/A
# dividends	206	--
Total Paid Out	$26.05	--
Avg. Dividend % Per Year	2.24%	--
Score	4.1	--
Div. Sustainability Score	1.990
Div.Growth Potential Score	2.67
Div. Directional Score	2.33	--

Next Divdend (Est)
(2024-07-01)

$0.413 Estimate 39.90 %

Dividend Stability

0.80 Good

Dividend Score

4.10

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.00731	0.90%
1973	$0.0138	1.60%
1974	$0.0156	1.83%
1975	$0.0160	2.52%
1976	$0.0170	3.03%
1977	$0.0196	3.44%
1978	$0.0231	4.27%
1979	$0.0261	3.98%
1980	$0.0285	3.84%
1981	$0.0316	3.01%
1982	$0.0364	3.50%
1983	$0.0460	3.43%
1984	$0.0524	3.66%
1985	$0.0584	3.65%
1986	$0.0648	3.27%
1987	$0.0712	2.91%
1988	$0.0792	4.13%
1989	$0.0868	3.81%
1990	$0.0948	3.37%
1991	$0.104	3.29%
1992	$0.117	1.77%
1993	$0.133	2.32%
1994	$0.149	2.77%
1995	$0.164	2.74%
1996	$0.190	1.93%
1997	$0.215	1.66%
1998	$0.240	1.00%
1999	$0.291	0.75%
2000	$0.342	1.13%
2001	$0.416	0.95%
2002	$0.492	1.30%
2003	$0.568	1.90%
2004	$0.644	1.91%
2005	$0.720	2.87%
2006	$0.912	4.04%
2007	$1.100	4.41%
2008	$1.216	5.59%
2009	$0.760	4.39%
2010	$0.684	3.81%
2011	$0.760	4.53%
2012	$0.836	4.01%
2013	$0.912	3.71%
2014	$0.988	3.42%
2015	$1.064	3.58%
2016	$1.140	3.76%
2017	$1.216	3.88%
2018	$1.292	3.74%
2019	$1.368	3.33%
2020	$1.444	3.89%
2021	$1.560	4.24%
2022	$1.600	2.82%
2023	$1.640	3.20%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.00561	1.500	-0.112	-0.168	[0 - 0.5]
returnOnAssetsTTM	-0.00136	1.200	-0.0455	-0.0546	[0 - 0.3]
returnOnEquityTTM	-0.00320	1.500	-1.147	-1.720	[0.1 - 1]
payoutRatioTTM	-29.93	-1.000	-10.00	10.00	[0 - 1]
currentRatioTTM	0.907	0.800	-0.467	-0.373	[1 - 3]
quickRatioTTM	0.499	0.800	-1.768	-1.415	[0.8 - 2.5]
cashRatioTTM	0.0597	1.500	-0.779	-1.169	[0.2 - 2]
debtRatioTTM	0.320	-1.500	4.67	-7.01	[0 - 0.6]
interestCoverageTTM	0.531	1.000	-0.914	-0.914	[3 - 30]
operatingCashFlowPerShareTTM	1.538	2.00	9.49	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.847	2.00	9.58	10.00	[0 - 20]
debtEquityRatioTTM	0.814	-1.500	6.75	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.507	1.000	4.89	4.89	[0.2 - 0.8]
operatingProfitMarginTTM	0.0258	1.000	-1.483	-1.483	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.120	1.000	-0.444	-0.444	[0.2 - 2]
assetTurnoverTTM	0.243	0.800	-1.712	-1.369	[0.5 - 2]
Total Score				1.990

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-509.13	1.000	-10.00	0	[1 - 100]
returnOnEquityTTM	-0.00320	2.50	-0.737	-1.720	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.847	2.00	9.72	10.00	[0 - 30]
dividendYielPercentageTTM	5.93	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.538	2.00	9.49	10.00	[0 - 30]
payoutRatioTTM	-29.93	1.500	-10.00	10.00	[0 - 1]
pegRatioTTM	23.65	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.158	1.000	8.55	0	[0.1 - 0.5]
Total Score				2.67

Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.